Daniele Nascimento Gouveia1, Adriana Gibara Guimarães2, Wagner Barbosa da Rocha Santos1, Lucindo José Quintans-Júnior1. 1. Departamento de Fisiologia, Laboratório de Neurociências e Ensaios Farmacológicos (LANEF). Universidade Federal de Sergipe, São Cristovão, Sergipe, Brazil. 2. Departamento de Educação em Saúde, Universidade Federal de Sergipe, Av. Governador Marcelo Déda, 13, Lagarto, Sergipe, Brazil. Electronic address: adrianagibara@pq.cnpq.br.
Abstract
BACKGROUND: Cancer is the leading cause of death in the world and one of the main symptoms affecting these individuals is chronic pain, which must be evaluated and treated in its various components. Several drugs are currently used, but beyond the high cost, they have harmful side effects to patients or are transitorily effective. Ergo, there is a need to look for new options for cancer pain relief. Natural products (NPs) present themselves as strong candidates for the development of new drugs for the treatment of chronic pain, such as cancer pain. PURPOSE: This systematic review aimed to summarize current knowledge about the analgesic profile of NPs in cancer pain. METHODS: The search included PubMed, Scopus and Web of Science (from inception to June 2018) sought to summarize the articles studying new proposals with NPs for the management of oncological pain. Two independent reviewers extracted data on study characteristics, methods and outcomes. RESULTS: After an extensive survey, 21 articles were selected, which described the analgesic potential of 15 natural compounds to relieve cancer pain. After analyzing the data, it can be suggested that these NPs, which have targets in central and peripheral mechanisms, are interesting candidates for the treatment of cancer pain for addressing different pharmacological mechanisms (even innovative), but ensuring the safety of these compounds is still a challenge. Likewise, the cannabinoids compounds leave the front as the most promising compounds for direct applicability due to the clinical studies that have already been developed and the background already established about these effects on chronic pain. CONCLUSION: Regarding these findings, it can be concluded that the variability of possible biological sites of action is strategic for new perspectives in the development of therapeutic proposals different from those available in the current market.
BACKGROUND: Cancer is the leading cause of death in the world and one of the main symptoms affecting these individuals is chronic pain, which must be evaluated and treated in its various components. Several drugs are currently used, but beyond the high cost, they have harmful side effects to patients or are transitorily effective. Ergo, there is a need to look for new options for cancer pain relief. Natural products (NPs) present themselves as strong candidates for the development of new drugs for the treatment of chronic pain, such as cancer pain. PURPOSE: This systematic review aimed to summarize current knowledge about the analgesic profile of NPs in cancer pain. METHODS: The search included PubMed, Scopus and Web of Science (from inception to June 2018) sought to summarize the articles studying new proposals with NPs for the management of oncological pain. Two independent reviewers extracted data on study characteristics, methods and outcomes. RESULTS: After an extensive survey, 21 articles were selected, which described the analgesic potential of 15 natural compounds to relieve cancer pain. After analyzing the data, it can be suggested that these NPs, which have targets in central and peripheral mechanisms, are interesting candidates for the treatment of cancer pain for addressing different pharmacological mechanisms (even innovative), but ensuring the safety of these compounds is still a challenge. Likewise, the cannabinoids compounds leave the front as the most promising compounds for direct applicability due to the clinical studies that have already been developed and the background already established about these effects on chronic pain. CONCLUSION: Regarding these findings, it can be concluded that the variability of possible biological sites of action is strategic for new perspectives in the development of therapeutic proposals different from those available in the current market.
Authors: Simone M Creed; Anna M Gutridge; Malaika D Argade; Madeline R Hennessy; J Brent Friesen; Guido F Pauli; Richard M van Rijn; Andrew P Riley Journal: J Nat Prod Date: 2020-12-16 Impact factor: 4.050
Authors: Billy Vinette; José Côté; Ali El-Akhras; Hazar Mrad; Gabrielle Chicoine; Karine Bilodeau Journal: BMC Cancer Date: 2022-03-24 Impact factor: 4.430